What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
about
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertensionThe altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic miceDifferent angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.Renin-angiotensin system in the kidney: What is new?Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the Taichung Diabetes Study.Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide.Efficacy and tolerability of telmisartan plus amlodipine in asian patients not adequately controlled on either monotherapy or on low-dose combination therapy.An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects.Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.Diltiazem reduces mortality and breakdown of ATP in red blood cell induced by isoproterenol in a freely moving rat model in vivo.
P2860
Q26824261-8F9331E5-1ABB-4483-BE5B-91BE3613EAC4Q28544698-993892F1-DB71-4D42-BB71-B89BE18DC012Q33689466-AEAA00A7-6322-4E1C-BBA1-18C76E13BA16Q34367671-E4FBB654-F8FE-47E3-A820-C62AB838F114Q36373025-46227997-7CA9-4551-968E-E0F526968B4CQ36448492-5F3289DE-6644-4337-A39D-2EF7D769EF0CQ36541873-F67244D6-FD76-4703-9230-2BFACC426230Q37053287-93BDB519-5860-4985-9458-EA222CDD9025Q37203105-9FDAAAAB-C592-4FF8-980B-194980BC25D7Q37639773-945D0B9E-B0C2-4765-9B3D-DB1F4C84438CQ38113242-E2C04C66-7593-4BBB-9A03-CAE22089B0E8Q38392298-24C2255F-FFC6-4D41-855A-0C501C4FE833Q41239847-487D4CD5-56F9-4295-B7D5-E8EC4C09F52FQ42939189-1F9C2A25-E88B-4FA9-8A7B-25AD12FF0FB7
P2860
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
What is a preferred angiotensi ...... non-diabetic renal impairment?
@ast
What is a preferred angiotensi ...... non-diabetic renal impairment?
@en
type
label
What is a preferred angiotensi ...... non-diabetic renal impairment?
@ast
What is a preferred angiotensi ...... non-diabetic renal impairment?
@en
prefLabel
What is a preferred angiotensi ...... non-diabetic renal impairment?
@ast
What is a preferred angiotensi ...... non-diabetic renal impairment?
@en
P2860
P356
P1476
What is a preferred angiotensi ...... non-diabetic renal impairment?
@en
P2093
Samir G Mallat
P2860
P2888
P356
10.1186/1475-2840-11-32
P407
P5008
P577
2012-04-10T00:00:00Z
P5875
P6179
1046537146